全文获取类型
收费全文 | 36369篇 |
免费 | 2414篇 |
国内免费 | 104篇 |
专业分类
耳鼻咽喉 | 624篇 |
儿科学 | 936篇 |
妇产科学 | 542篇 |
基础医学 | 4359篇 |
口腔科学 | 508篇 |
临床医学 | 3947篇 |
内科学 | 7120篇 |
皮肤病学 | 441篇 |
神经病学 | 3265篇 |
特种医学 | 1480篇 |
外科学 | 6201篇 |
综合类 | 417篇 |
一般理论 | 42篇 |
预防医学 | 3274篇 |
眼科学 | 563篇 |
药学 | 2692篇 |
中国医学 | 31篇 |
肿瘤学 | 2445篇 |
出版年
2023年 | 239篇 |
2022年 | 189篇 |
2021年 | 876篇 |
2020年 | 655篇 |
2019年 | 1041篇 |
2018年 | 1236篇 |
2017年 | 878篇 |
2016年 | 878篇 |
2015年 | 1045篇 |
2014年 | 1565篇 |
2013年 | 2040篇 |
2012年 | 2971篇 |
2011年 | 3057篇 |
2010年 | 1590篇 |
2009年 | 1486篇 |
2008年 | 2559篇 |
2007年 | 2543篇 |
2006年 | 2350篇 |
2005年 | 2319篇 |
2004年 | 2196篇 |
2003年 | 1975篇 |
2002年 | 1826篇 |
2001年 | 242篇 |
2000年 | 216篇 |
1999年 | 262篇 |
1998年 | 290篇 |
1997年 | 212篇 |
1996年 | 200篇 |
1995年 | 177篇 |
1994年 | 179篇 |
1993年 | 150篇 |
1992年 | 117篇 |
1991年 | 113篇 |
1990年 | 99篇 |
1989年 | 90篇 |
1988年 | 84篇 |
1987年 | 74篇 |
1986年 | 71篇 |
1985年 | 73篇 |
1984年 | 77篇 |
1983年 | 86篇 |
1982年 | 91篇 |
1981年 | 68篇 |
1980年 | 46篇 |
1979年 | 40篇 |
1978年 | 30篇 |
1977年 | 31篇 |
1976年 | 21篇 |
1975年 | 20篇 |
1970年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
2.
Thom T. J. Veeger Nienke M. van de Velde Kevin R. Keene Erik H. Niks Melissa T. Hooijmans Andrew G. Webb Jurriaan H. de Groot Hermien E. Kan 《NMR in biomedicine》2022,35(7):e4691
In Becker muscular dystrophy (BMD), muscle weakness progresses relatively slowly, with a highly variable rate among patients. This complicates clinical trials, as clinically relevant changes are difficult to capture within the typical duration of a trial. Therefore, predictors for disease progression are needed. We assessed if temporal increase of fat fraction (FF) in BMD follows a sigmoidal trajectory and whether fat fraction at baseline (FFbase) could therefore predict FF increase after 2 years (ΔFF). Thereafter, for two different MR-based parameters, we tested the additional predictive value to FFbase. We used 3-T Dixon data from the upper and lower leg, and multiecho spin-echo MRI and 7-T 31P MRS datasets from the lower leg, acquired in 24 BMD patients (age: 41.4 [SD 12.8] years). We assessed the pattern of increase in FF using mixed-effects modelling. Subsequently, we tested if indicators of muscle damage like standard deviation in water T2 (stdT2) and the phosphodiester (PDE) over ATP ratio at baseline had additional value to FFbase for predicting ∆FF. The association between FFbase and ΔFF was described by the derivative of a sigmoid function and resulted in a peak ΔFF around 0.45 FFbase (fourth-order polynomial term: t = 3.7, p < .001). StdT2 and PDE/ATP were not significantly associated with ∆FF if FFbase was included in the model. The relationship between FFbase and ∆FF suggests a sigmoidal trajectory of the increase in FF over time in BMD, similar to that described for Duchenne muscular dystrophy. Our results can be used to identify muscles (or patients) that are in the fast progressing stage of the disease, thereby facilitating the conduct of clinical trials. 相似文献
3.
4.
5.
6.
7.
Nathanson S. David Detmar Michael Padera Timothy P. Yates Lucy R. Welch Danny R. Beadnell Thomas C. Scheid Adam D. Wrenn Emma D. Cheung Kevin 《Clinical & experimental metastasis》2022,39(1):117-137
Clinical & Experimental Metastasis - Invasive breast cancer tends to metastasize to lymph nodes and systemic sites. The management of metastasis has evolved by focusing on controlling the... 相似文献
8.
9.
Lombardo Joseph Ko Kevin Shimada Ayako Nelson Nicolas Wright Christopher Chen Jerry Maity Alisha Ruggiero Marissa L. Richard Scott Papanagnou Dimitrios Mitchell Edith Leader Amy Simone Nicole L. 《Cancer causes & control : CCC》2022,33(4):559-582
Cancer Causes & Control - A disparity exists in cancer screening rates for the Sexual and Gender Minority (SGM) community. We sought to understand the perceptions and baseline knowledge of... 相似文献
10.
Tara O. Henderson MD MPH Brynn W. Fowler MPH Haley A. Hamann MPH Paul C. Nathan MD MSc Jillian Whitton MS Wendy M. Leisenring ScD Kevin C. Oeffinger MD Joseph P. Neglia MD MPH Lucie M. Turcotte MD MPH MS Michael A. Arnold MD PhD Miriam R. Conces MD Rebecca M. Howell PhD Leslie L. Robison PhD Gregory T. Armstrong MD MSCE Kenneth A. Alexander MD PhD 《Cancer》2022,128(2):373-382